Protagenic Therapeutics, Inc.\new
PTIX, PTIXWOther · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating income | −$5.7M | −$4.5M | −$3.6M | −$4.1M | −$2.6M | −$2.1M |
| Net income | −$5.5M | −$5.0M | −$3.6M | −$4.5M | −$2.5M | −$1.8M |
| Total assets | $2.0M | $4.3M | $8.0M | $11.1M | $879,247 | $842,273 |
| Total liabilities | $942,759 | $655,252 | $1.1M | $1.1M | $2.0M | $1.5M |
| Equity | $1.0M | $3.7M | $6.9M | $9.9M | −$1.1M | −$634,366 |
| EPS (diluted) | $-1.13 | $-1.15 | $-0.82 | $-1.24 | — | — |
| Shares out. | 4.4M | 4.3M | 17.3M | 10.5M | 10.3M | 10.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −545.4%
- Return on assets
- −282.5%
- Return on capital (ROCE)
- −562.7%
- Liabilities / assets
- 48.2%
- Debt / equity
- 0.93×
- Book value / share
- $0.23
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -75.81distress
- Accruals / assets
- −66.9%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 18, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2017
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bigger Capital Fund L PPassive (13G)Aug 25, 2025
- Armistice Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Arrow Alexander K.Officer — Chief Financial Officer | Oct 12, 2023 | Buy | 8,000 | $0.81 |
| Arrow Alexander K.Officer — Chief Financial Officer | May 17, 2022 | Buy | 23,000 | $0.71 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 7, 2026
- Director / officer changeMar 3, 2026
- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Other material eventFeb 24, 2026
- Delisting / listing-standard noticeJan 5, 2026
- Delisting / listing-standard notice · Regulation FD disclosureNov 26, 2025
- Director / officer changeNov 5, 2025
- Other material eventOct 31, 2025
- Delisting / listing-standard notice · Changed auditor · Regulation FD disclosureAug 22, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.